Please login to the form below

Not currently logged in
Email:
Password:

David Holliday joins Octapharma USA as VP commercial development

Moves from Baxter Bioscience to take up senior sales and marketing role in the US

David Holliday - Octapharma USAOctapharma USA has appointed Baxter Bioscience's former VP of global marketing operations and haemophilia as its new VP of commercial development.

David Holliday will lead all US product marketing, sales and commercial activities at Octapharma, along with co-ordinating its global portfolio development initiatives.

The company is the US affiliate of Swiss-headquartered Octapharma AG, which develops and manufactures human protein products.

Holliday spent eight years at Baxter, gaining US and international experience in management, sales, marketing and business development, and was responsible for several successful product launches.

Prior to his time at Baxter, he held leadership positions at both Novartis and Ciba-Geigy Pharmaceuticals.

“We are very excited to have David Holliday, a true global leader in our industry, join our senior management team,” said Octapharma's USA president, Flemming Nielsen.

“He joins Octapharma USA at an extremely important time for our company as our product portfolio in the US will be increasing significantly in the next year and we expect David will be integral to our growth.”

26th January 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics